Cargando…

Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors

LKB1 and KRAS are the third most frequent co-mutations detected in non-small cell lung cancer (NSCLC) and cause aggressive tumor growth. Unfortunately, treatment with RAS-RAF-MEK-ERK pathway inhibitors has minimal therapeutic efficacy in LKB1-mutant KRAS-driven NSCLC. Autophagy, an intracellular nut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatt, Vrushank, Lan, Taijin, Wang, Wenping, Kong, Jerry, Lopes, Eduardo Cararo, Wang, Jianming, Khayati, Khoosheh, Raju, Akash, Rangel, Michael, Lopez, Enrique, Hu, Zhixian Sherrie, Luo, Xuefei, Su, Xiaoyang, Malhotra, Jyoti, Hu, Wenwei, Pine, Sharon R., White, Eileen, Guo, Jessie Yanxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879981/ https://www.ncbi.nlm.nih.gov/pubmed/36702816 http://dx.doi.org/10.1038/s41419-023-05592-8

Ejemplares similares

Autophagy modulates lipid metabolism to maintain metabolic flexibility for Lkb1-deficient Kras-driven lung tumorigenesis
por: Bhatt, Vrushank, et al.
Publicado: (2019)

Autophagy compensates for Lkb1 loss to maintain adult mice homeostasis and survival
por: Khayati, Khoosheh, et al.
Publicado: (2020)

G6PD Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung Cancer
por: Lan, Taijin, et al.
Publicado: (2023)

Leukemia inhibitory factor drives glucose metabolic reprogramming to promote breast tumorigenesis
por: Yue, Xuetian, et al.
Publicado: (2022)

Amino acid metabolites, mTORC1 and aging
por: Antikainen, Henri, et al.
Publicado: (2017)

Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells
por: Mondal, Arindam, et al.
Publicado: (2022)

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1-mutant lung cancer
por: Kim, Jiyeon, et al.
Publicado: (2020)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Glutamine synthetase limits β-catenin–mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1
por: Dai, Weiwei, et al.
Publicado: (2022)

KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes
por: McKenzie, Andrew J., et al.
Publicado: (2016)

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
por: Kim, Jiyeon, et al.
Publicado: (2017)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

CPT1A and fatty acid β-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer
por: Jariwala, Nidhi, et al.
Publicado: (2021)

Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer
por: Lee, Hyunmin, et al.
Publicado: (2022)

Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition
por: Sheppard, Sarah E., et al.
Publicado: (2023)

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest
por: Morton, Jennifer P., et al.
Publicado: (2010)

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells
por: Della Corte, Carminia Maria, et al.
Publicado: (2015)

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
por: Hu, Haoyue, et al.
Publicado: (2020)

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
por: Lyons, Yasmin A., et al.
Publicado: (2014)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
por: Vidal-Cruchez, Olivia, et al.
Publicado: (2023)

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status
por: Zhang, Jun, et al.
Publicado: (2017)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2
por: Wong, Gabrielle S., et al.
Publicado: (2018)

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
por: Ogishima, Juri, et al.
Publicado: (2018)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2018)

Autophagy promotes mammalian survival by suppressing oxidative stress and p53
por: Yang, Yang, et al.
Publicado: (2020)

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
por: Zhou, Wei, et al.
Publicado: (2014)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Autophagy maintains tumor growth through circulating arginine
por: Poillet-Perez, Laura, et al.
Publicado: (2018)

SOX4-SMARCA4 complex promotes glycolysis-dependent TNBC cell growth through transcriptional regulation of Hexokinase 2
por: Khanna, Pooja, et al.
Publicado: (2023)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
por: Qu, Shuang, et al.
Publicado: (2022)

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
por: Mahoney, C L, et al.
Publicado: (2009)

Snail acetylation by autophagy‐derived acetyl‐coenzyme A promotes invasion and metastasis of KRAS‐LKB1 co‐mutated lung cancer cells
por: Han, Jang Hee, et al.
Publicado: (2022)

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
por: Hata, Aaron N, et al.
Publicado: (2017)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
por: Cheon, Seul‐Ki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_21j2ferbrt119gf74qgb0pmi1e